New accelerator MedTecX aims to help bring innovative medical device technologies to the rapidly changing China market.
Start-ups are developing transcatheter treatments for a type of heart failure that has been increasing in prevalence: heart failure with preserved ejection fraction. HFpEF is a huge potential device market because it appears to develop from an accumulation of damages that come with aging rather than a specific cause like heart attack or valve dysfunction.
Competitors in the diabetes market are working to meet consumer demand for more digitally integrated and interconnected diabetes management solutions, and collaborations among the various participants represent the new norm in this industry. In this ICYMI, Big pharma Eli Lilly partners with medtech to shift its diabetes focus from molecules to outcomes.
Robotics were the hot topic at NASS 2018, but discussions also raged about advanced implant materials that have the potential to promote better bone growth and faster healing and reduce reliance on expensive biologics to achieve those goals. An excerpt from Senior Writer Wendy Diller’s November 16 feature, “At NASS 2018, Advanced Biomaterials and the Pull of Robots.”
Apple recently made a splash with its new ECG-enabled watch, but technology from an Israeli start-up may have a better chance of penetrating the multibillion-dollar ambulatory cardiac arrhythmia monitoring market. An excerpt from Executive Editor Mary Thompson’s October 31 feature, “Ambulatory ECG Monitoring Enters a New, More Patient-Friendly Era.”
Last November, FDA issued a long-awaited, final guidance on its standards for overseeing human cell and tissue products. It is the latest move in an ongoing effort by the agency to wrap its arms around the complex, evolving, and controversial area of tissue-based biologics and, by extension, the newer, fast-growing field of regenerative medicine. An excerpt from Senior Writer Wendy Diller’s October 17 feature, “Regulatory Shifts for HCT/P Products Put Orthobiologics Manufacturers on the Spot.”
Neuro-focused prescription digital health companies are taking aim at a range of diseases from psychiatric and mental health disorders to neurodegenerative diseases. In this excerpt from our September 28 feature, “Digital Taps Into Neurological Function,” Mark Ratner talks with William Marks, MD, about Verily Life Sciences’ activities in the field.
Carbon’s unique 3D liquid interface process creates the products it prints out of a pool of liquid, an approach that it says overcomes the challenges of traditional layering. The well-funded start-up has partnered with big players in numerous industries. Johnson & Johnson invested in its latest financing round, which points toward opportunities in medtech. An excerpt from Editor-in Chief David Cassak’s recent profile of Carbon.
Conventional wisdom has held that medtech companies could only be successful if they were willing and able to tackle the US market, but two decades ago Biosensors International built an extremely successful interventional cardiology business by bypassing the US to target Japan and, at the time, a nascent Chinese market. We share an excerpt from David Cassak’s conversation with Biosensors’ former CEO Yoh-Chie Lu.
The stem cell therapies market is booming, thanks to ongoing unmet clinical needs, demographics, marketing, and advances in technology, but medical professionals are grappling with lack of evidence for most applications. Senior writer Wendy Diller explored stem cells’ use in orthopedics in our June 27 issue, and noted the exponential growth of financing for companies in the field.
Joe Almeida joined Baxter International as CEO in 2016, shortly after Medtronic merged with his previous company, Covidien. When he came on board, Baxter’s strategy was diffuse. The company had morphed from its hospital supply roots in many different directions, including the 2015 launch of a biotechnology company, Baxalta. The public perception was that Baxter had lost its way. Enter Almeida, to bring focus to the company and restore its culture of innovation. In this week’s #ICYMI, we share an excerpt of Almeida’s comments on his five-year plan for Baxter’s product portfolio.